



Journal of Anatomical
Sciences

Email:anatomicaljournal@gmail.com

J Anat Sci 8 (1)

Antioxidant, hypolipidemic and Hypoglycemic Effect of Ethanol Leaf Extract of *Chrysophyllum albidum* on Streptozotocin- Induced Diabetic Rats.

¹Idaguko CA, ²Duru FIO and ²Oremosu AA

¹Department of Anatomy, Madonna University. Elele Campus. Rivers State.

²Department of Anatomy. College of Medicine, University of Lagos, LUTH-Idi Araba

Corresponding Author: Idaguko CA

E-mail: annachi67@yahoo.com

ABSTRACT

The purpose of the present study was to investigate the antioxidant and anti-diabetic effect of *Chrysophyllum albidum* in streptozotocin-induced diabetic rats. Fifty Sprague-Dawley rats (170-200g) were used, of which twenty rats were randomised into four groups (n= 5). Group A received normal saline 10 ml. Group B, C and D received *C. albidum* by gavage at a dose of 125, 250 and 500 mg/kg respectively. The prophylactic study was performed with thirty rats divided into six groups (n=5). Groups E and F received only normal saline; group G received 2 mg/kg of glibenclamide; groups H, I and J received 125, 250, and 500 mg/kg/day of ethanolic leave extracts of *C. albidum* respectively. With the exception of group E, animals in groups F-J was challenged with 50 mg/kg of streptozotocin intraperitoneally after two weeks of oral administration of normal saline, extract and glibenclamide. Administration of normal saline, extract and glibenclamide was continued for another two weeks. The animals were fasted overnight before they were sacrifice on day 14th and their blood samples and pancreas were collected for biochemical assays. Results showed significant elevation in Superoxide dismutase, Catalase, and Glutathione activities ($p < 0.05$); and decrease in malondialdehyde. The extract significantly increased ($p < 0.05$) High density lipoprotein and also significantly reduced ($p < 0.05$) Low density lipoprotein, Triglycerides and Total cholesterol. It can be concluded that *C. albidum* possesses hypoglycemic, antioxidant and hypolipidemic potentials, thereby justifying support for its anti-diabetic use in folk medicine.

Keywords: *Chrysophyllum albidum*, Diabetes, Streptozotocin, Oxidatives stress, lipid profile

INTRODUCTION

Diabetes mellitus is a metabolic disorder that is marked by elevated blood glucose concentration and excretion of glucose in urine¹. It is usually associated with oxidative stress, accompanied by excessive production of free radicals². Elevated generation of ROS and the simultaneous decline in antioxidative defense mechanisms observed in diabetic patients could promote the development of complications associated with diabetes mellitus³, such complications include cardiovascular disorders, blindness, renal failure, neuropathies, and cancers^{4,5}.

Abnormal lipid metabolism causes deranged levels of Total Cholesterol, Triglycerides, Low density lipoprotein, High density lipoprotein, which is one of the reasons for premature atherosclerosis in patients with diabetes mellitus⁶. The non-insulin-dependent diabetic (NIDDM) patient with mild fasting hyperglycemia commonly has mild hypertriglyceridemia due to overproduction of TG-rich lipoproteins in the liver, associated with decreased high-density lipoprotein levels⁷. High levels of triglycerides in the bloodstream have been linked to atherosclerosis and, by extension, the risk of heart disease and stroke⁸.

Many herbal products have been prescribed for the management of diabetes mellitus in ancient and recent literature⁹. Available literatures show that there are more than 400 plant species showing anti-diabetic activity with the possible use in the treatment of DM and its complications¹⁰. Several plant extracts have been examined for their antidiabetic properties in an attempt to recognize alternative treatment strategies that pose less of a hazard for diabetics¹¹.

Chrysophyllum albidum. (Family: Sapotaceae) has many common names including white star apple agbalumo (Yoruba), udara (Igbo) and agwaluma (Hausa). It is a popular tropical fruits widely distributed in Nigeria. The plant *C. albidum* have been employed in folk medicine for the treatment of diseases. The seeds from the cotyledons are used as ointments in the treatment of vaginal and dermatological infections in Western Nigeria and also possess anti-hyperglycemic and hypolipidemic effects¹². Hypoglycemic, Antioxidant and Hepatoprotective activities of the root bark has been reported¹³. The root bark has been known to have antifertility effect¹⁴, also the bark is used as a remedy for yellow fever and malaria while the leaves are used as emollients and for treatment of skin

eruption, diarrhoea and stomach ache^{15, 16} and also has antiplatelet effect¹⁷. The fruit pulp is rich in vitamin C and iron and an excellent source of raw material for industries^{15, 18}. The purpose of this study is to evaluate the effects of *C. albidum* on the hypoglycemic, oxidative stress markers and lipid profiles on STZ-induced diabetes using Sprague-Dawley rats.

MATERIALS AND METHODS

Plant material

The fresh leaves of *C. albidum* were collected on September, 2015 in Elele of Rivers State, and authenticated by Mr O. O. Oyebanji, a taxonomist in the Department of Botany, University of Lagos, Nigeria. It was assigned a voucher number LUH 7458 and was deposited in the herbarium for future reference.

Plant extraction

C. albidum leaves were air dried for two weeks and then blended into powder. The method used was as described by¹⁹. The powdered leaves of *C. albidum* two kilograms were soaked in 17 L of ethanol in a glass jar for four days at room temperature, after which the extract was filtered using a What man no. 1 filter paper and cotton wool. It was concentrated at 50°C using a rotary evaporator and further concentrated using water bath at 48°C. The yield of the ethanol extract was found to be 168 g giving a percentage yield of 21.6 %. The extract was stored in a beaker covered with aluminium foil and stored in a refrigerator at 4°C until when needed.

Experimental Animals

Fifty adult Sprague-Dawley rats of both sexes (170-200g) were obtained from the breeding colony of the National Institute of Medical Research (NIMR) Yaba, Lagos. They were housed in cages at room temperature under standard conditions and maintained in a 12h light/dark cycle. The animals were fed on pelletized growers feed and water *ad libitum*. The animals were allowed to acclimatize for two weeks in the animal house of the Department of Anatomy, University of Lagos, Nigeria before commencement of the experiment.

Experimental design and treatments

A (Hypoglycaemic study)

Study on normoglycemic animals

Four groups of five rats each were fasted overnight. Group A received distilled water 10 ml. Group B, C and D received the *C. albidum* that is administered by gavage at a dose of 125, 250 and 500 mg/kg body weight respectively. Blood samples were drawn by puncture from the tail immediately at 0, 4hr, 8hr and 12 hrs to check for blood glucose levels^{20,21}.

Experiment B (Prophylactic study)

Induction of experimental diabetes

Experimental diabetes mellitus was induced by a single intra-peritoneal injection of a freshly prepared streptozotocin (STZ) solution (Sigma, St. Louis, MO, USA) (50 mg/kg in cold citrate buffer 0.1 M, pH

4.5) to overnight fasted rats. Seventy two (72) hours after STZ injection, blood was taken from tail vein of the rats. Animals having blood glucose levels $\geq 300\text{mg/dl}$ were considered diabetic and included in the study.

Animals grouping and Administration of *C. albidum*

The prophylactic study was performed with 30 rats of both sexes randomly divided into 6 groups (E-J) of five rats per group: groups E and F received only normal saline; group G received 2 mg/kg of glibenclamide; groups H, I and J received 125, 250, and 500 mg/kg/day of the leave extract respectively. With the exception of group E, animals in groups F-J was challenged with 50 mg/kg of streptozotocin intraperitoneally after two weeks of oral administration of normal saline, extract and the dosage of glibenclamide. The animals were considered as being diabetic if the blood glucose values were $\geq 300\text{mg/dl}$ 72 hours after STZ injection.

Treatment was continued for another two weeks, blood glucose levels were measured every three days during the experimental period after which the animals were fasted overnight, anaesthetized under chloroform fumes, sacrificed and their sera collected for biochemical assay.

Biochemical analysis

Blood Glucose Level (BGL) was measured with Accu-check^(R) Active glucose strips in Accu-check Active^(R) (Roche Diagnostic, Mannheim, Germany) test meter and expressed as mg/dl, using blood obtained from the tail vein of overnight fasted rats

Antioxidant Enzymes Assay

Superoxide Dismutase (SOD) activity was determined by method described by²². Catalase activity was determined according to²³. The reduced glutathione (GSH) content was estimated according to the method described by²⁴. Malondialdehyde (MDA) an index of lipid peroxidation was determined using the method of²⁵.

Plasma Lipid Profile Determination

Plasma Total cholesterol (TC) levels, Plasma Triglyceride (TG), High Density Lipoprotein (HDL) were determined using a Randox diagnostic kit^{26,27}. Low Density Lipoprotein (LDL) was calculated using the empirical equation of²⁸.

Estimation of serum insulin level

The estimation of serum insulin levels was done by radio-immunoassay (RIA) using Mercodia Ultrasensitive Rat Insulin (INS) ELISA Kit (Catalog. No: WAR-617).

Ethical approval

All authors hereby declare that "Principles of laboratory animal care" (NIH publication No. 85-23, revised 1985) were followed. All experiments were examined and approved by the College of Medicine University

of Lagos Health Research Ethics Committee and were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.

Statistical analysis

Statistical analysis was performed using GRAPH PAD Prism software package, Version 5.0. All the data were expressed as mean \pm standard deviation (SD). The comparison within groups was evaluated utilizing independent Turkey T test and one way analysis of variance (ANOVA). The value of $p < 0.05$ was considered to be statistically significant.

RESULTS

Hypoglycaemic effect of *C. albidum* on normal rats

In the hypoglycaemic study as shown in table 1, there was appreciable decrease in glycaemic level in groups C and D (47.6 ± 6.28 and 46.6 ± 10.54) when compared to the control group A (51.6 ± 6.89). However, at group B, significant ($p < 0.05$) decrease occurs after 4 hour of the oral administration of the extract (48.2 ± 8.35) also, the hypoglycaemic effect produced at 12 hour was more (33.6 ± 8.87).

Table 1: Hypoglycaemic assessments of *C. albidum* leave extract

Group	0 hr	4hr	8hr	12hr
A	71.8 ± 8.13	61.2 ± 7.86	56.4 ± 6.05	51.6 ± 6.89
B	72.4 ± 9.75	$48.2 \pm 8.35^*$	$42.6 \pm 7.92^*$	$33.6 \pm 8.87^*$
C	70.0 ± 3.35	56.4 ± 4.41	51.8 ± 6.11	47.6 ± 6.28
D	74.8 ± 5.85	63.8 ± 13.41	55.4 ± 14.15	46.6 ± 10.54

Values are expressed as mean \pm SD of $n = 5$ per group. *represents significant difference when compared with A ($p < 0.05$)

Key: A= Control, B= *C. albidum* 125 mg/kg, C= *C. albidum* 250 mg/kg, D= *C. albidum* 500 mg/kg

Pancreatic anti-oxidant status of *C. albidum* leaf activity

The table 2 showed the activities of antioxidant enzymes and malondialdehyde (MDA). There was a statistically significant ($p < 0.05$) decrease in the diabetic untreated group F in reduced glutathione (GSH), superoxide dismutase (SOD) and Catalase (CAT) activities and increase in the MDA content when compared to group E (control). The GSH and CAT activities and MDA content in group G (glibenclamide)

and the treated groups (H, I and J) showed no significant difference, however, there was appreciable increase of SOD and CAT at 125mg/kg (group H) when compared to the control (group E). There was a statistical significant ($p < 0.05$) increase in GSH, SOD and CAT activities in glibenclamide and treated groups with appreciable increase in CAT at a dose of 125 mg/kg group H, however with significant ($p < 0.05$) decrease in MDA when compared to the diabetic untreated group F.

Table 2: Effect of *C. albidum* on pancreatic oxidative stress parameters

GROUP	DOSE	GSH	SOD	CAT	MDA
	mg/kg	$\mu\text{mol/ml/mg}$	$\mu\text{mol/ml/min/mg}$	$\mu\text{mol/ml/min/mg}$	$\mu\text{mol/ml/mg}$
	Bw/Day	Protein	Protein	Protein	Protein
E	10 ml	0.82 ± 0.24	2.80 ± 0.03	20.24 ± 0.17	0.06 ± 0.03
F	10 ml	$0.49 \pm 0.01^*$	$1.44 \pm 0.01^*$	$7.63 \pm 0.80^*$	$1.40 \pm 0.00^*$
G	2	$0.81 \pm 0.05^\wedge$	$2.45 \pm 0.17^{*\wedge}$	$18.35 \pm 0.14^\wedge$	$0.05 \pm 0.03^\wedge$
H	125	$0.76 \pm 0.01^\wedge$	$1.70 \pm 0.08^{*\wedge}$	$11.45 \pm 0.06^*$	$0.06 \pm 0.01^\wedge$
I	250	$0.76 \pm 0.01^\wedge$	$2.55 \pm 0.18^{*\wedge}$	$15.42 \pm 0.19^\wedge$	$0.04 \pm 0.01^\wedge$
J	500	$0.75 \pm 0.01^\wedge$	$1.73 \pm 0.01^{*\wedge}$	$13.38 \pm 0.22^\wedge$	$0.05 \pm 0.00^\wedge$

Values are expressed as mean \pm SD. $N = 5$ in each group. * = significant difference when compared with E ($p < 0.05$). $^\wedge$ = significant difference when compared with F ($p < 0.05$)

KEY: E=control- Distilled water, F= Diabetic control (normal saline), G= 2mg/kg Glibenclamide, H= 125 mg/kg *C. albidum*, I= 250 mg/kg *C. albidum*, J= 500 mg/kg *C. albidum*

GSH: Glutathione; SOD: Superoxide dismutase; CAT: Catalase; MDA: Malondialdehyde

Effect of *C. albidum* on serum lipid profile

Serum levels of total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-c) was increased significantly ($p<0.05$) in Diabetic Control (group F) in respect to the control (group E). The treated groups (G, H, I and J) showed significant recovery ($p<0.05$) when compared to the control group E, except the *C. albidum* at a dose of 500 mg/kg (group J) for CHOL and TG at 125 mg/kg (group H) which

were significantly ($p<0.05$) increased and decreased respectively when compared to the control group E. This study also showed serum high density lipoprotein cholesterol (HDL-c) concentration level was decreased significantly ($p<0.05$) as a result of the effect of diabetes, which was severe in the Diabetic Control group when compared to the control (group E). The treated groups showed significant recovery ($p<0.05$) when compared to the Diabetic Control (group F)

Table 3: Effect of treatment on serum lipid profile

GROUPS	DOSE mg/kg bw/day	TC nmol/L	TG nmol/L	HDL-C nmol/L	LDL-C nmol/L
E	10 ml	0.71 ±0.04	0.64± 0.01	0.81±0.09	0.18±0.02
F	10 ml	2.53±0.07*	1.29±0.08*	0.42±0.05*	1.08±0.06*
G	2	0.66±0.07^	0.64± 0.00^	0.74±0.09 ^	0.18±0.06^
H	125	0.75±0.03^	0.50±0.04*^	0.71±0.01^	0.18±0.01^
I	250	0.72±0.02^	0.61±0.03^	0.86 ± 0.03^	0.21±0.03^
J	500	0.88±0.04* ^	0.63±0.01^	0.82±0.03^	0.23±0.01^

Values are expressed as mean± SD. N= 5 in each group. *= significant difference when compared with E ($p<0.05$). ^= significant difference when compared with F ($p<0.05$)

CHOL: Cholesterol, TG: Triglyceride, HDL-C: High density lipoprotein, LDL-C: Low density lipoprotein

Effects of *C. albidum* on serum Insulin level

To assess insulin secretion in these animals, fasting insulin levels (Table 4; at 0 and 30 min) in diabetic untreated group was significantly decreased ($p<0.05$) when compared to the control. However, there was a significant ($p<0.05$) positive impact on insulin levels in the glibenclamide (2 mg/kg) and treated groups (H, I and

J) when compared to the diabetic untreated group F. When plasma insulin levels were measured 30 min after a glucose challenge in rats, it was found that circulating insulin levels were significantly reduced in the diabetic untreated. However, treatment with glibenclamide and *C. albidum* resulted in a significant ($p<0.05$) increase in insulin level when compared to the diabetic untreated.

Table 4: Effect of *C. albidum* on insulin level

Groups	0 min	30 mins
E	13.63 ±0.72	14.31±0.58
F	3.29±0.49*	2.80±0.52*
G	6.47±0.50*^	7.45±0.57*^
H	5.54±0.62*^	6.32±0.74*^
I	6.05±0.64 *^	7.40±0.73*^
J	6.14±0.64*^	7.74±0.62*^

Values are expressed as mean± SD. N= 5 in each group. *= significant difference when compared with E ($p<0.05$). ^= significant difference when compared with F ($p<0.05$)

DISCUSSION

In the hypoglycaemic study, the activities of *C. albidum* were evaluated with normal rats. At doses of 250 and 500 mg/kg, the leaf showed appreciable hypoglycaemic effects. But at 125 mg/kg, a significant ($p < 0.05$) decrease in glycaemia was observed. It has been observed that hypoglycaemic activities occur from the stimulation of pancreatic beta cells to release insulin²⁹.³⁰ reported the phytochemicals, alkaloids, flavonoids, tannins and glycosides to have hypoglycaemic effects in normoglycaemic rats. Glycosides are implicated with strong hypoglycaemic activities³¹. It is therefore presumed that these active components present in the extract were largely responsible for the hypoglycaemic effects.

Oxidative stress has been suggested as mechanism underlying diabetes mellitus and diabetic complications³². Hyperglycemia in diabetes mellitus causes a depletion of the cellular antioxidant defences and increases the levels of free radicals³³. Abnormal elevated levels of free radicals and the simultaneous reduction of antioxidant defense can result in damage of cellular organelles and enzymes, increased lipid peroxidation and development of insulin resistance³⁴. These enzymes play an important role in maintaining physiological levels of oxygen and hydrogen peroxide by hastening the dismutation of oxygen radicals and eliminating organic peroxides and hydroperoxides generated from inadvertent exposure to STZ³⁵. Superoxide dismutase (SOD), a metallo protein is the most sensitive and most important enzyme in the enzymatic antioxidant defense system. It scavenges the superoxide anion to form hydrogen peroxide and oxygen, hence diminishing the toxic effect caused by this radical³⁶. While Catalase (CAT) is an enzymatic antioxidant widely distributed in all tissues. It is a heme protein, localized in the peroxisomes or the microperoxisomes. This enzyme catalyses the decomposition of H_2O_2 to water and oxygen and thus protecting the cell from oxidative damage by H_2O_2 and OH. Therefore, the reduction in the activity of catalase may result in a number of deleterious effects due to accumulation of hydrogen peroxide³⁷. The pancreas has a relatively weak intrinsic defense system against oxidative stress³⁸, hence the need to protect it from oxidative stress.

In this study, the pancreatic oxidative status, shows the decreased activity of SOD, CAT and GSH of diabetic animals, in addition the increase in malondialdehyde (MDA) levels in pancreas suggests enhanced lipid peroxidation leading to tissue damage and failure of antioxidant defense mechanisms to prevent formation of excessive free radicals. Treatment with ethanol extract of *C. albidum* significantly increases the antioxidant enzymes and decrease in MDA was observed. These findings suggest that the *C. albidum* may exert antioxidant activity and protect the tissue from lipid peroxidation.

Abnormalities of lipid profile are one of the most common metabolic complications of diabetes mellitus which is found in about 40% of diabetes³⁹. Dyslipidemia which includes not only quantitative but also qualitative abnormalities of lipoprotein plays a significant role in the proatherogenesis of vascular complications in diabetes mellitus⁴⁰. Insulin is a potent inhibitor of the lipolysis⁴¹, the lack of insulin and elevations of the counter-regulatory hormones lead to activation of enzymes (hormone-sensitive lipase) that stimulate lipolysis and enhanced release of free fatty acids from adipose tissue⁴⁰. The fatty acids from adipose tissues are mobilized for energy purpose and excess fatty acids are accumulated in the liver, which are converted to triglyceride⁴². The increased free fatty acid concentration promotes the production of more acetyl co A and cholesterol⁴¹. The marked hyperlipidemia that characterizes the diabetic state may therefore be regarded as a consequence of unlimited actions of lipolytic hormones on the fat depots⁴³.

When much LDL-cholesterol circulates in the blood, it can slowly build up in the inner walls of the arteries that feed the heart and brain. It can also form plaque that narrows the arteries, a condition known as atherosclerosis. An elevated level of triglyceride is a consistent feature in diabetic dyslipidemia⁴⁴. Hence there is need for a reduction in the concentration of total cholesterol, triglyceride and LDL-cholesterol in the blood. Moreso, prior to the full manifestation of DM, individuals often exhibit an atherogenic pattern of risk factors that include lower level of HDL-cholesterol⁴⁵. HDL-c function to remove cholesterol antheroma within arteries and transport it back to the liver for its excretion or reutilization, thus high level of HDL-C protect against cardiovascular disease^{46,47}.

From this study, there was a marked increase in the lipid content which led to different lipid abnormalities in streptozotocin induced diabetic rat. Thus, it can be concluded from our findings that the administration of the ethanolic leaf extract of *C. albidum* due to its antihyperlipidemic activity, may be helpful in decreasing LDL-c, TC and TG which was actually elevated and also increase HDL-c, which was also decreased in hyperlipidaemic rats. In addition, its antihyperlipidemic effect could represent a protective mechanism against the development of atherosclerosis.

Thus, the significantly reduced serum insulin level recorded in the present study showed that STZ administration caused destruction to insulin producing β -cell in the pancreas. This finding has been reported by other investigators^{48, 49}. Based on the appreciable increases in plasma insulin levels in rats treated with *C. albidum* extracts, it can be suggested that the possible mechanism of action of ethanolic extract

from *C. albidum* could be related to anti-oxidant activity that aids recovery from impaired glucose metabolism through release of insulin from the pancreas. *C. albidum* may serve as a significant indicator of its potential antioxidant activity in mopping up the free radicals produced by STZ.

CONCLUSION

In conclusion, extract of *C. albidum* has demonstrated strong hypoglycemic, antioxidant and anti-lipidemic and should be evaluated further to determine its possible mechanism(s) of action(s)

ACKNOWLEDGEMENTS

The authors of this work wish to thank Mr. O. Ayegbusi of the Department of Chemical Pathology, Ahmadu Bello University Teaching Hospital (ABUTH), Zaria and Mr Adelekan of the Department of Biochemistry and Mr Otu Duncan of the Department of Human Physiology, College of Medicine, University of Lagos, Nigeria, for their technical assistance to ensuring that this study was successful.

COMPETING INTERESTS

Authors have declared that no competing interests exist

REFERENCES

1. El-Wakf A, Tarek MA, Rizk AE, Wafaa A. Role of Hypertension and Metabolic Abnormalities in the Development of Diabetic Nephropathy among Egyptian Patients with Type 2 Diabetes. *Nature Sci.* 2011; 7(9):220-228.
2. Sayyed SG, Kumar A, Sharma SS. Effects of U83836E on nerve functions, hyperalgesia and oxidative stress in experimental diabetic neuropathy. *Life Sci.* 2006; 79(8):777-783.
3. Sharma B, Kumar S, Siddiqui S, Ram G, Chaudhary M. Ameliorative effects of aqueous leaf extract of *Aloe arborescens* on anti-hyperglycaemia and antihyperlipidaemia alterations in alloxan-induced diabetic mice. *J. Invest. Biochem.* 2013; 2(2):71-76.
4. Mansour HA, Newairy ASA, Yousef MI, and S. A. Sheweita SA. Biochemical study on the effects of some Egyptian herbs in alloxan-induced diabetic rats. *Toxicology*, 2002; 170(3):221-228.
5. American Diabetes Association. "Diagnosis and classification of diabetes mellitus," *Diabetes Care*. 2006; 29 (1): s43-s48.
6. Khanna AK, Ramesh C, Kapoor NK. Terminalia ayurvedic cardi tonic regulates lipid metabolism in hyperlipidemic rats. *Phytotherapy Research*. 1996; 10: 663-669.
7. Abbate SL, Brunzell JD. Pathophysiology of hyperlipidaemia in diabetes mellitus. *J. Cardiovasc Pharmacol* 1990; 9: 81-87.
8. Davidson MH, Toth PP, Maki KC. *Therapeutic Lipidology. Contemporary Cardiology*. Cannon, Christopher P.; Armani, Annemarie M. Totowa, New Jersey: Humana Press, Inc. pp. 141-142. 2008.
9. World Health Organization (WHO). Global status report on noncommunicable diseases 2010. Geneva: World Health Organization.
10. Shafi S, Tabassum N, Ahmad F. Diabetic Nephropathy and Herbal Medicines. *Int. J. Phytopharmacol.* 2012; 3(1):10-17.
11. Adeyi AO, Nneji LM. and Idowu BA. Ameliorative potentials of medicinal plants on the pathophysiological complications of diabetes mellitus: A review. *J. Med. Plants Res.* 2015; 9(8):262-288.
12. Olorunnisola DS, Amao IS, Ehigie DO, Ajayi ZAF. Anti-Hyperglycemic and Hypolipidemic Effect of Ethanolic Extract of *Chrysophyllum albidum* Seed Cotyledon in Alloxan Induced-Diabetic Rats. *Res. J. Appl. Sci.* 2008; 3: 123-127.
13. Onyeka CA, Nwakanma AA, Bakare AA, Okoko II, Ofego UC, Wali CC, Abengowe FC. Hypoglycemic, Antioxidant and Hepatoprotective Activities of Ethanolic Root Bark Extract of *Chrysophyllum albidum* in Alloxan-Induced Diabetic Rats. *Bangladesh J of Medical Sci.* 2013; 12(03): 298-304.
14. Onyeka CA, Aligwekwe AU, Olawuyi TS, Nwakanma AA, Kalu EC, Oyeyemi AW. Antifertility Effects of Ethanolic Root Bark Extract of *Chrysophyllum albidum* in Male Albino Rats. *Int J of Applied Res in Natural Products.* 2012; 5 (1): 12-17.
15. Adisa SA. Vitamin C, Protein and Mineral content of African Apple (*Chrysophyllum albidum*) in proceedings of the 18th Annual Conference of NIST. (eds) Garba SA, Ijagbone IF Iyagba AO, Iyamu AO, Kiliani AS, Ufaruna N, 2000; 141-146.
16. Idowu TO, Iwalewa EO, Aderogba MA, Akinpelu BA, Ogundaini AO. Biochemical and behavioural effects of eleagnine from *Chrysophyllum albidum*. *J. Biol. Sci.* 2006; 6: 1029-1034.
17. Adebayo AH, Abolaji AO, Opatu TK and Adegbenro IK. Effects of ethanolic leaf extract of *Chrysophyllum albidum* G. on biochemical and haematological parameters of albino Wistar rats. *African J of Biotechnology*. 2010; 9(14): 2145-2150.
18. Akubugwo IE, Ugbogu AE. Physicochemical studies on oils from five selected Nigerian plant seeds. *Pak. J. Nutr.* 2007; 6: 75-78.
19. Adebayo AH, Aliyu R, Gatsing D, Garba IH. The Effects of Ethanolic Leaf Extract of *Commiphora africana* (Burseraceae) on Lipid Profile in Rats. *Int. J. Pharmacol.* 2006; 2: 618-622.
20. Sharma SR., Dwivedi SK., Swarup D. Hypoglycaemic potential of *Mangifera indica* leaves in rats. *International J of Pharmacognosy.* 1997; 35:130-133.
21. Rajkumar S and Kumar NS. Isolation chemical characterization and hypoglycemic activity of *Alangium salviifolium* wang back in alloxan induced hyperglycemic rats *IJSP.* 2011; 2(6):1518-1524.
22. Sun M, Zigma S. An improved spectrophotometric

- assay of superoxide dismutase based on epinephrine autoxidation. *Anal Biochem.* 1978; 90:81-89.
23. Aebi H. Catalase in vitro. In: Colowick SP, Kaplan NO eds. *Methods in Enzymol.* 1984; 105:121-126.
24. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. *Anal Biochem.* 1968; 25: 1192-1205.
25. Buege JA, Aust SD. Microsomal lipid peroxidation. *Methods Enzymol.* 1978; 52: 302-310.
26. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. *Annals of Clin Biochem.* 1969; 6:24
27. Tietz NW. *Clinical guide to laboratory tests*, second edition WB Saunders Company, Philadelphia, USA 554-556. 1990.
28. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin. Chem.* 1972; 18:499-502
29. Shalev, A. Hope for insulin mimetic oral antidiabetic drugs. *European J of Endocrinology.* 1999; 141: 561-562.
30. Adeneye AA, Adeyemi OO. Hypoglycaemic effects of the aqueous seed extract of *Hunteria umbellata* in normoglycaemic and glucose and nicotine-induced hyperglycaemic rats. March-April. *Int. J. Appl. Res. Nat. Prod.* 2009; 2(1):9-18.
31. Abdel-hassan IS, Abdel-Barry JA, Mohammeda ST. The hypoglycemic and antihyperglycemic effect of *Citrullus coccyntis* fruit aqueous extract in normal and alloxan diabetic rabbits. *J Ethnopharmacol.* 2000; 71:325-330
32. Kanchana G, Shyni WJ, Malini P, Rajadurai M. Effect of sinapic acid on antiperoxidative and antioxidant potential in normal and streptozotocin-induced diabetes in Wistar rats. *Int J Pharm Clin Res.* 2011;3:5-9.
33. Tsuruta R, Fujita M, Ono T, Koda Y, Koga Y, Yamamoto T, et al. Hyperglycemia enhances excessive superoxide anion radical generation, oxidative stress, early inflammation, and endothelial injury in forebrain ischemia/reperfusion rats. *Brain research.* 2010; 1309:155-163.
34. Kumar R, Kar B, Dolai N, Bala A, and Haldar PK, Evaluation of antihyperglycaemic and antioxidant properties of *Streblus asper* against streptozotocin-induced diabetes in rats. *Asian Pacific J of Tropical Disease.* 2012; 2(2): 139-143.
35. Latha M. and Pari L. Antihyperglycemic effect of *Cassia auriculata* in experimental diabetes and its effects on key metabolic enzymes involved in carbohydrate metabolism. *Clin Exp Pharmacol Physiol.* 2003; 30:38-48
36. Olaleye M, Afolabi C, Adebayo A, Ogunboye A and Akindahunsi A, Antioxidant activity and hepatoprotective property of leaf extracts of *Boerhaavia diffusa* Linn against acetaminophen-induced liver damage in rats, *Food Chem Toxicol.* 2010; 48: 2200-2205.
37. Curtis S.J, Moritz M and Snodgrass P.J, Serum enzymes derived from liver cell fractions and the response to carbon tetrachloride intoxication in rats, *Gastroenterology.* 1972; 62: 84-92.
38. Hui MJ, Dong CZ, Hui FG, Qing YQ, Shun KF, Xiao LL et al. Antioxidant N-Acetylcysteine Protects Pancreatic β -Cells Against Aldosterone-Induced Oxidative Stress and Apoptosis in Female db/db Mice and Insulin-Producing MIN6 Cells. *Endocrinology.* 2013; 154(11): 4068-4077.
39. Ravi K, Rajasekaran S. Subramanian. Antihyperglycemic effect of *Eugenia jambolana* Seed kernel on streptozotocin-induced diabetes in rats. *Food Chem. Toxicology.* 2005; 43: 1433-1439.
40. Rotimi SO, Omotosho OE, Rotimi OA. Persistence of acidosis in alloxan induced diabetic rats treated with the juice of *Asystasia gangetica* leaves. *Phcog. Mag.* 2011; 7: 25-30.
41. Saravanan R, Pari L. Antihyperlipidemic and antiperoxidative effect of diasulin, a polyherbal formulation in alloxan induced hyperglycemic rats. *BMC complementary and Alternative Medicine.* 2005; 5: 1472-6882/5/14
42. Suryawanshi NP, Bhutey AK, Nagdeote AN, Jadhavand AA, Manoorkar GS. Study of lipid peroxide and lipid profile in diabetes mellitus. *Indian J. Clinic. Biochem.* 2006; 1: 126-130.
43. Claudia ENM., Julius EO, Dagobert T and Etienne D. Antidiabetic and hypolipidemic effects of *Laportea ovalifolia* (Urticaceae) in alloxan-induced diabetic rats. *Afr. J. Trad. Complementary Alternative Med.* 2006; 3(1): 36-43.
44. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particles sizes and concentration determined by nuclear magnetic resonance. *Diabetes.* 2003; 52:453-462.
45. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implication for preventing coronary heart disease during the prediabetic state. *Circulation.* 2000; 101: 975-980.
46. James DB, Owolabi OA, Ibrahim AB, Folorunsho DF, Bwalla I and Akanta F. Changes in lipid profile of aqueous and Ethanol extract of *Blighiasapida* in rats. *Asian J. Med. Sci.* 2010; 2:177-180.
47. Owolabi OJ, Omogbai EKI. Evaluation of the potassium channel activator levcromakalim (BRL38227) on the lipid profile, electrolytes and blood glucose levels of streptozotocin-diabetic rats. *J Diab* 2013; 5: 88-94.
48. Eze DE, Aliyu M, Yusuf T, Abubakar A, Karimah MR. Hypoglycemic Effect of Lycopene in Streptozotocin-Induced Diabetic Wistar Rats. *BJMMR.* 2015; 7(9):762-770.